GSK shares gain about 1.5% after rating and price target raised by Berenberg

Traders Union
All News
Stocks
Gsk rises 1.53% today to GBX1888

Highlights

Berenberg upgraded GSK stock to Buy from Hold and increased its price target from £20 to £22.
GSK is projected to post mid- to high-single-digit revenue and adjusted earnings growth in 2026.
Shares of GSK trade near the upper end of the intraday range, with overbought signals and potential for a downside move toward GBX1,846.

Analyst rating boost and growth forecasts drive improved sentiment

Berenberg upgraded its rating on GSK plc from Hold to Buy on September 15, 2026. The price target for GSK was increased from 20 to 22 GBP. GSK is forecast to achieve mid- to high-single-digit revenue and adjusted earnings growth for 2026.

Anton Kharitonov, expert at Traders Union, sees GSK's bounce as mainly technical and tied to the upgrade. However, the price remains locked below both the 50-day and 200-day moving averages, showing persistent long-term pressure. Oscillators are overbought, but core momentum signals stay bearish. He is wary of the probability skew toward downside in the coming days. "Intraday buyers may run out of steam quickly, so I would guard against chasing GSK at current levels."

Viktoras Karapetjanc, expert at Traders Union, notes Berenberg’s rating upgrade as a strong vote of confidence. He sees upgraded earnings and revenue forecasts as reinforcing GSK’s bullish structure. While current levels face resistance, the outlook for mid- to high-single-digit growth supports further gains. Karapetjanc believes the market will offer new upside setups soon. "GSK’s improved fundamentals provide a strong foundation for continued advancement — further growth looks likely from here."

Sholanke Dele, market strategist, remains cautious despite today's reaction. He points out mixed signals from momentum indicators and overbought conditions, warning of a potential near-term pullback. Dele sees the wide five-day trading band and 67% downside probability as evidence of uncertainty. "Until buyers reclaim higher moving averages, I see more risk than reward in GSK."

Overbought signals clash with bearish momentum as resistance nears

GSK is trading above its 20-day moving average (GBX1,855), but remains below the 50-day (GBX1,893) and 200-day (GBX1,951) moving averages. This structure signals short-term strength is building, yet medium- and longer-term selling pressure persists. The Ichimoku Kijun at GBX1,853 acts as support. The closest support is the intraday floor at GBX1,868 and resistance at the near-term ceiling of GBX1,889. Momentum signals are mixed, with the MACD showing strong selling momentum and ADX indicating a neutral trend. The RSI stands at 52.09 (buy), CCI at 50.89 (buy), and Stochastic RSI at 83.12 (overbought). Bull/Bear Power is strongly positive at 58.66, highlighting continued buying and overbought conditions. GSK is up to GBX1,888 on the day, with the price near the top of today’s GBX1,868–GBX1,889 range and intraday volatility at 1.12%. While intraday strength is evident, divergences between overbought oscillators and negative momentum indicators suggest upside momentum may stall soon.

Earlier, analysts noted that GSK's technical outlook was marked by mixed momentum signals and a tendency toward short-term consolidation. The latest price action confirms these dynamics, with current levels reinforcing a rangebound setup and making GBX1,846 and GBX1,921 the critical levels to watch for any upcoming breakout or breakdown.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.